# Investigating Safety, Tolerability and Efficacy of AZD5363 in Prostate Cancer.

> **NCT01692262** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 59 (actual)

## Conditions studied

- Metastatic Castrate-Resistant Prostate Cancer (mCRPC),
- Efficacy,
- Safety and Tolerability,
- Pharmacokinetics,
- Pharmacodynamics,
- Tumour Response.

## Interventions

- **DRUG:** Intermittent dosing of AZD5363
- **DRUG:** Intermittent dosing of AZD5363
- **DRUG:** Intermittent dosing of AZD5363

## Key facts

- **NCT ID:** NCT01692262
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11
- **Primary completion:** 2014-06
- **Final completion:** 2014-06
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2014-06-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01692262

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01692262, "Investigating Safety, Tolerability and Efficacy of AZD5363 in Prostate Cancer.". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01692262. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*